Gemcitabine pulmonary toxicity: CT features.
The purpose of this case report is to describe the CT imaging features of pulmonary toxicity from gemcitabine, a relatively new chemotherapeutic agent, in three patients. CT features of gemcitabine pulmonary toxicity include ground glass opacity (n = 3), thickened septal lines (n = 3), and reticular opacities (n = 3). Distribution is diffuse and bilateral, and may be symmetric (n = 2) or asymmetric (n = 1). Clinical symptoms and imaging findings are potentially reversible with steroid therapy.
Boiselle
P M
PM
Department of Radiology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA. pboisell@caregroup.harvard.edu
Morrin
M M
MM
Huberman
M S
MS
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D003841:Deoxycytidine / Q000009:adverse effects* / Q000031:analogs & derivatives; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging / Q000187:drug effects*; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000000981:diagnostic imaging; D008175:Lung Neoplasms / Q000188:drug therapy; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D000093542:Gemcitabine
D000893:Anti-Inflammatory Agents; D000964:Antimetabolites, Antineoplastic; D005938:Glucocorticoids; D003841:Deoxycytidine; D011241:Prednisone; D000093542:Gemcitabine